Efficacy, Safety and Tolerability of Co-artemether in Non-immune Travelers
Status:
Completed
Trial end date:
2005-08-01
Target enrollment:
Participant gender:
Summary
This study will assess the safety and efficacy of co-artemether in the treatment of acute
uncomplicated P. falciparum malaria in returning non-immune travellers
THIS STUDY IS NOT ENROLLING PATIENTS IN THE UNITED STATES
Phase:
Phase 4
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Artemether Artemether-lumefantrine combination Artemether, Lumefantrine Drug Combination Artemisinins